Fabian Gerlinghaus (Cellares)

Fo­cused on the cell ther­a­py man­u­fac­tur­ing bot­tle­neck, Cel­lares tur­bocharges plans for 'shut­tle' tech

When Cel­lares CEO and co-founder Fabi­an Ger­ling­haus tore his ACL a few years ago, he was brought out­side of a Bay Area hos­pi­tal to the park­ing lot where he re­ceived an MRI in­side a truck. He and his col­leagues hope that the same can be done for cell ther­a­py — one day — and they just re­ceived $82 mil­lion in fund­ing to help do so.

Cel­lares on Wednes­day bagged a Se­ries B round, bring­ing its to­tal fund­ing to $100 mil­lion so far. Those funds will be used to de­vel­op the Cell Shut­tle, a portable fac­to­ry that Cel­lares hopes will dis­rupt the ex­pen­sive and lo­gis­ti­cal­ly com­pli­cat­ed cell ther­a­py man­u­fac­tur­ing process.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.